Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2

Figure 1

Chemiluminescence-linked immunoassay (CLISA)-quantified phosphorylated Akt (P-Akt) levels. (a) Histogram showing distribution of chemiluminescence-linked immunoassay (CLISA)-determined phosphorylated Akt (P-Akt) expression levels in 156 primary breast cancer samples. P-Akt levels ranged from 0 to 1.08 U/mg, with a median of 0.17 U/mg. (b) Scatter plot of P-Akt versus ErbB-2 expression levels. No correlation was found between the levels of P-Akt and ErbB-2.

Back to article page